Daxxify vs Botox vs Dysport: A 2026 Comparison

A 41-year-old woman sits down in my treatment chair in Columbus and tells me she wants Daxxify because she read that it lasts six months and she is tired of coming in every three. Her last provider used 20 units in her glabella and she felt frozen for the first month and then "completely back to normal" by week eight. She wants the longer-lasting option so she can deal with this less often. She does not want to look frozen again.

This is a representative version of the conversation I have several times a week. The product question is almost never the right starting point. The dose, the placement, and the muscle dynamics matter more than which of the three neuromodulators ends up in the syringe. After 17 years between emergency medicine, the cardiac ICU, and the cath lab, I learned to ask why before I touched a needle, and aesthetic injectables are no different. The face is anatomy, not branding.

The three molecules and what actually distinguishes them

All three are botulinum toxin type A. They all work by blocking acetylcholine release at the neuromuscular junction, which prevents the targeted muscle from contracting fully. The muscle does not atrophy. It does not die. It simply stops firing for a defined window while the nerve terminal regenerates new SNARE proteins to resume signaling.

Where they differ is in the protein structure surrounding the toxin and how that affects diffusion, onset, and duration.

Botox (onabotulinumtoxinA) is the original. The complex includes accessory proteins that keep the active toxin tightly localized to the injection point. Onset is around 3 to 5 days, full effect at 10 to 14 days, and average duration is 3 to 4 months. The dose-response and diffusion profile is the most predictable of the three because we have the most clinical experience with it.

Dysport (abobotulinumtoxinA) has a smaller accessory protein complex and a slightly faster onset, often 2 to 3 days. It diffuses a bit more from the injection point, which can be an advantage in broader areas like the forehead and a disadvantage in tight, precise zones near the brow elevators. Unit conversion is roughly 2.5 to 3 Dysport units per Botox unit, which trips up patients comparing prices.

Daxxify (daxibotulinumtoxinA) is the newer molecule, FDA-approved in 2022 for glabellar lines and 2023 for cervical dystonia. The distinguishing feature is a peptide excipient that increases binding affinity at the nerve terminal, which extends median duration to roughly 6 months in the clinical trials and 4 to 6 months in real-world use. Onset is comparable to Botox.

The duration claim is the marketing story. The clinical reality is that response varies widely by patient, by muscle group, and by metabolic factors. Some patients metabolize neuromodulators faster than the trial averages predict. Others get 5 months out of standard Botox. The product alone does not determine the duration you experience.

Why the longer-duration product is not always the right answer

The patient who sat down asking for Daxxify because she wanted to "deal with this less often" is the patient I most often steer toward the conservative option for the first round, regardless of which product we use. Here is why.

If the dose is wrong, or the placement is slightly off, or the muscle balance produces a result you do not love, you live with that result for the entire duration of the product. With Botox or Dysport, that is 3 to 4 months. With Daxxify, that is 5 to 6. A heavy brow, a flattened expression, or an asymmetry that bothers you is a much bigger problem when it lasts twice as long.

I tell first-time patients, and patients new to my practice, that we are calibrating. The first treatment is data collection. I want to see how your specific muscles respond to a defined dose at defined points, then refine from there at the 2-week follow-up and again at the next treatment cycle. Once I have that data — usually after one or two cycles — switching to a longer-duration product is a reasonable conversation. Starting there is not.

What I look for at the consultation

Before I draw up anything, I want to see the face in motion. A static photo and a forehead at rest tells me almost nothing. I ask patients to raise their brows, frown hard, squint, smile, purse their lips, and lift their chin. I am watching for:

• The dominant elevators and depressors in the upper third — which muscles are doing the most work, and how they balance against each other
• Compensatory recruitment — patients who have been treated before often recruit accessory muscles to produce expressions they are accustomed to making
• Asymmetry at baseline that needs to be preserved or partially corrected
• Skin quality and laxity — a heavily etched static line in thin, sun-damaged skin will not soften with neuromodulator alone, and I would rather tell you that upfront than take your money and disappoint you
• Brow position and lid distance — over-treatment of the frontalis in a patient with brow ptosis will produce a heavy, hooded look that takes months to resolve

I also ask about prior treatments and what the patient liked and disliked about each. "I felt frozen" tells me to dose more conservatively in the depressors. "It wore off too fast" sometimes means the dose was too low and sometimes means the patient is a fast metabolizer. "My brows looked weird" usually means the frontalis got too much relative to the corrugators.

How I think about candidate selection between the three

For a first-time neuromodulator patient who has never seen what their face looks like in a partially relaxed state, I almost always start with Botox or Dysport. The shorter duration gives us a calibration window and a clean reset if anything needs adjusting. I tend toward Botox in the glabella where precision matters and toward Dysport in the broader forehead where slightly more diffusion can produce a smoother result with fewer injection points.

For an established patient who knows their response pattern, has a stable maintenance schedule, and is asking specifically to extend the interval between treatments, Daxxify is a reasonable conversation. The dose conversion is roughly 1:1 with Botox in most areas, and the technique is the same. Patients who travel often, patients with demanding professional schedules, and patients who simply prefer fewer touchpoints are the ones for whom the longer duration translates into real lifestyle value.

For patients with a history of brow heaviness, lid ptosis, or significant asymmetry, I am more conservative across all three products. I would rather under-treat and add at the 2-week follow-up than over-treat and wait six months for resolution.

What the [neuromodulator treatments](/services/neuromodulators) plan looks like in practice

A first treatment in my practice runs 15 to 30 minutes once we are in the chair. The consultation is the work. The injection itself is brief. I dose conservatively on round one, document the units and placement on a face map, and have you back at 2 weeks for assessment and any touch-up. If you are under-treated at 2 weeks, we add. If the result is dialed in, we set the maintenance interval based on how you metabolize the product — usually 12 to 16 weeks for Botox and Dysport, 16 to 24 weeks for Daxxify.

I rarely recommend neuromodulators in isolation if the patient's broader concerns include skin quality, texture, or static lines that the muscle relaxation alone will not address. In those cases the conversation also includes microneedling, VI Peel, or fractional CO2 laser depending on the depth of the concern, and sometimes dermal filler treatments for volume changes that contribute to the appearance of lines. The AquaFirme facial and the vampire facial are other tools I use for skin quality between injectable visits.

The honest conversation about cost and value

Daxxify costs more per unit than Botox or Dysport. If you respond to it for 6 months and you would otherwise need Botox at 3 months, the per-year cost is comparable or sometimes lower. If you respond to it for 4 months — which is closer to the lower end of real-world experience — the math changes. I tell patients to budget for two to three Daxxify treatments per year and adjust based on individual response, not the marketing claim of twice-yearly dosing.

I am not loyal to any product. I carry all three because patients respond differently and because some areas of the face are genuinely better served by one molecule over another. The product I reach for is the one that fits the specific patient's anatomy, history, and goals — not the one with the highest margin or the longest duration.

Your concrete next step

If you are considering neuromodulator treatment for the first time, or if you have been treated before but felt the result did not match what you wanted, the right next step is a 30-minute in-person consultation. Bring photos of yourself from before any prior treatment if you have them, the names and approximate doses of any products you have received, and a list of the specific things you liked and disliked about prior results. We will assess your face in motion, map the dosing plan, and decide together whether Botox, Dysport, or Daxxify is the right starting product for your first round in my chair. Book online or call either the Columbus or Warner Robins office directly. I rotate between both locations on a published schedule, and the protocols I use are identical at each.

TW

Travis Woodley

MSN, RN, CRNP — Platinum Biote Provider — Founder, Revitalize

Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.

Book a ConsultationCall (762) 261-3880

About Travis →More articles →Rebuild Institute →